Table 1.
Source and description of samples used in the study
| Sample source | Disease | Number | Female, no. (%) | Age (range) | anti-CCP positive, no. (%) | RF positive, no. (%) |
| Dr. P. Gregersen, plasma set 1 | RA | 30 | 28 (93) | 72.6 (51 to 89) | 20 (67) | 24 (80) |
| Healthy | 10 | |||||
| Dr. P. Gregersen, plasma set 2 | IBD | 20 | 13 (65) | 46.4 (23 to 82) | ||
| JRA | 20 | 16 (80) | 37.3 (10 to 71) | 6 (30) | 6 (30) | |
| PsA | 14 | 11 (79) | 52.6 (23 to 75) | |||
| PS | 20 | 10(50) | 55.3(22 to 86) | |||
| RA | 20 | 19(95) | 59.0(35 to 89) | |||
| SLE | 20 | 13 (65) | 51.3 (29 to 67) | |||
CCP, cyclic-citrullinated peptides; RF, rheumatoid factor; RA, rheumatoid arthritis; IBD, inflammatory bowel disease; JRA, juvenile rheumatoid arthritis; PsA, psoriatic arthritis; PS, psoriasis; SLE, systemic lupus erythematosus.